BAYER’S Eylea (aflibercept) has
been listed on the Pharmaceutical
Benefits Scheme effective 01
Oct for the treatment of diabetic
macular oedema (DME) in adults.
Eylea has also been PBS listed
from this month for the treatment
of visual impairment due to macular
oedema secondary to central
retinal vein occlusion (CRVO).The above article was sent to subscribers in Pharmacy Daily's issue from 08 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Oct 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.